Senhwa Biosciences announced yesterday (July 16) that its investigational new drug Pidnarulex (CX-5461) has been selected for a five-year cancer treatment program sponsored by the U.S. National Cancer Institute (NCI). The first clinical trial under this program—evaluating Pidnarulex as a monotherapy for advanced solid tumors—has successfully enrolled its first patient at the NIH Clinical Center in Bethesda, Maryland, USA. The NCI will fund the clinical trial with an estimated budget of USD 4.8 million, significantly reducing Senhwa's R&D burden and accelerating drug development.
In addition to covering the USD 4.8 million clinical costs for this initial monotherapy trial, the NCI is also leading three other cutting-edge human clinical trials involving Pidnarulex. These include trials combining the drug with immunotherapy, with antibody-drug conjugates (ADCs), and as a monotherapy for MYC-aberrant lymphomas. All three studies are actively progressing, with IND submissions and full-scale patient enrollment expected soon.
The initial monotherapy study under the NCI program will investigate the ability of CX-5461 to induce Rad51 response in patients with and without homologous recombination deficiency (HRD) gene mutations. The trial is expected to explore additional biomarkers and assess the potential for synthetic lethality with CX-5461. The goal is to identify patient subgroups who are more responsive to the treatment and to broaden its potential indications. A total of 40 patients are expected to be enrolled. The study will cover costs related to clinical trial sites, pharmacokinetics (PK), biomarker analysis, as well as regulatory compliance, data management, and electronic platform implementation.
CX-5461 is a novel small-molecule drug candidate under development by Senhwa and represents a first-in-class therapeutic approach. Its mechanism of action selectively targets and stabilizes G-quadruplex (G4) DNA structures, inhibiting G4 unwinding, which leads to replication-dependent DNA damage and ultimately induces cancer cell apoptosis. G4 structures are prominently expressed in tumor tissues, particularly in actively transcribed genes, suggesting a functional role in cancer progression. By targeting these structures and inducing DNA damage in cancer cells, CX-5461 demonstrates strong potential as a therapeutic agent across various types of cancer.
With the global incidence of cancer continuing to rise—particularly among younger populations—the cancer drug market has seen significant growth. Among the most promising areas is immunotherapy, which harnesses the body’s immune system to combat cancer and has shown robust demand.
According to a recent report by Grand View Research, Inc., the global cancer immunotherapy market is projected to reach USD 224.3 billion by 2030, with a compound annual growth rate (CAGR) of 8.3% from 2024 to 2030.
Resource: 美NCI贊助生華科新藥計畫 首項單劑使用試驗啟動收案
